Glenmark complets Phase I clinical trials for GRC 6211

Mumbai, May 28 (UNI) Glenmark Pharmaceuticals Ltd today announced that its Swiss subsidiary, Glenmark Pharmaceuticals S A (GPSA), has completed Phase I clinical trials for GRC 6211 in Europe.

GRC 6211 is its lead Vanniloid Receptor (VR1) antagonist compound for a range of pain indications like naturopathic pain, osteoarthritis and urinary incontinence, the company said in a disclosure to the Bombay Stock Exchange (BSE).

The Company plans to initiate a large Phase IIB study in the first quarter of Calander Year 2008 for naturopathic pain and osteoarthritis. To ensure the timely start of Phase IIB by early 2008, various non-clinical studies are currently ongoing, the company said.

The Phase I study was conducted on 72 healthy human subjects using single and multiple oral doses with the objectives of assessing safety and pharmacokinetics of GRC 6211. It was found that GRC 6211 was well tolerated by the subjects at all dosages levels and was found to have a good safety profile and predictable pharmacokinetic properties.

Commenting on the company's achievement, Glenn Saldanha, Managing Director and CEO of the Company said, ''Glenmark now has three molecules in Phase II and expects another three to enter clinical testing over the next six months.'' The Company aims to be an early launcher in this class and targets launching the molecule in 2011. The Company is in discussions with potential partners for licensing this compound.

UNI